News & Events

HTG Molecular Diagnostics Announces VERI/O Laboratory Service

TUCSON, Ariz., June 23, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced the introduction of its Tucson‑based VERI/O laboratory service, offering laboratory support for its biopharma clients in biomarker research and companion diagnostic development. The VERI/O laboratory service formalizes and expands HTG’s traditional service offerings, including molecular profiling of retrospective cohorts to support development of targeted and immuno-oncology therapies, building custom research-use-only (RUO) assays to support early stage clinical programs, and developing companion diagnostic assays for use in Phase III registration trials.

Read More

HTG Molecular Appoints New Vice President of North American Capital Sales for the HTG EdgeSeq Platform

TUCSON, Ariz., June 20, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for NGS-based molecular profiling applications, today announced the appointment of Suzanne Hill as Vice President of North American Capital Sales.

Read More

HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

TUCSON, Ariz. and LOS ANGELES, June 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3–7, 2016 in Chicago, IL.

Read More

HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb

TUCSON, Ariz., May 12, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb’s translational research activities.

Read More

HTG Molecular Diagnostics Reports First Quarter 2016 Results

TUCSON, Ariz., May 12, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three months ended March 31, 2016.

Read More

Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics

TUCSON, Ariz., May 03, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Donnie (Don) M. Hardison has been appointed to its Board of Directors (“Board”).

Read More

HTG Molecular Diagnostics to Hold 2016 First Quarter Financial Results Conference Call on May 12, 2016

TUCSON, Ariz., May 02, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 first quarter financial results after market close on Thursday, May 12, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Thursday, May 12 to discuss these results and answer questions.

Read More

HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and Portugal

TUCSON, Ariz., April 11, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.

Read More

HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2015 Results

TUCSON, Ariz., March 24, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the fourth quarter and year ended December 31, 2015 and updates on key recent activities.

Read More

HTG Molecular Diagnostics Announces IVD Development and Supply Agreement with Thermo Fisher Scientific

TUCSON, Ariz., March 21, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has entered into a long-term agreement with Thermo Fisher Scientific under which HTG will have the right to develop a number of in-vitro diagnostic (IVD) tests for use with Thermo Fisher’s next-generation sequencing Ion PGM Dx System.

Read More

HTG Molecular Diagnostics to Hold 2015 Fourth Quarter and Full Year Financial Results Conference Call on March 24, 2016

TUCSON, Ariz., March 15, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2015 fourth quarter and full year financial results after market close on Thursday, March 24, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Thursday, March 24 to discuss these results and answer questions.

Read More

HTG Molecular Diagnostics Establishes Immuno-Oncology Scientific Advisory Board

TUCSON, Ariz., Feb. 16, 2016 (GLOBE NEWSWIRE) – In a release issued under the same headline earlier today by HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), please note that in the header for the fourth paragraph of the release, the HTG SAB member should be Ignacio I. Wistuba, M.D. and not Ignatio I. Wistuba, M.D. as previously stated. The corrected release follows:

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced the establishment of a Scientific Advisory Board (“SAB”) of distinguished leaders in the field of immuno-oncology. The newly formed SAB will serve as a resource to HTG in the development of immuno-oncology applications and biomarker panels for the assessment of the host immune response to tumors.

Read More